These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 14517122

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA, Jarrín I, del Amo J, Iribarren JA, Moreno S, Viciana P, Peña A, Sirvent JL, Vidal F, Lacruz J, Gutierrez F, Oteo JA, Asencio R, Castilla J, Hoyos SP, CoRIS-MD.
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B, MANIF 2000 Study Group.
    Antivir Ther; 2005 Aug; 10(1):53-61. PubMed ID: 15751763
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, Tyndall M, Wood E.
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [Abstract] [Full Text] [Related]

  • 12. Outpatient pharmacy care and HIV viral load response among patients on HAART.
    Castillo E, Palepu A, Beardsell A, Akagi L, Yip B, Montaner JS, Hogg RS.
    AIDS Care; 2004 May; 16(4):446-57. PubMed ID: 15203413
    [Abstract] [Full Text] [Related]

  • 13. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, Montaner JS.
    JAMA; 2008 Aug 06; 300(5):550-4. PubMed ID: 18677027
    [Abstract] [Full Text] [Related]

  • 14. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C, Muñoz A.
    Clin Infect Dis; 2007 Aug 01; 45(3):370-6. PubMed ID: 17599317
    [Abstract] [Full Text] [Related]

  • 15. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.
    BJOG; 2013 Nov 01; 120(12):1534-47. PubMed ID: 23924192
    [Abstract] [Full Text] [Related]

  • 16. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.
    Clin Infect Dis; 2006 Jan 01; 42(1):136-44. PubMed ID: 16323104
    [Abstract] [Full Text] [Related]

  • 17. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.
    HIV Med; 2007 May 01; 8(4):213-9. PubMed ID: 17461848
    [Abstract] [Full Text] [Related]

  • 18. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.
    J Infect Dis; 2004 Sep 15; 190(6):1046-54. PubMed ID: 15319852
    [Abstract] [Full Text] [Related]

  • 19. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.
    Mehta SH, Lucas G, Astemborski J, Kirk GD, Vlahov D, Galai N.
    AIDS Care; 2007 May 15; 19(5):637-45. PubMed ID: 17505924
    [Abstract] [Full Text] [Related]

  • 20. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar 15; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.